Prosonix has announced that a Phase 2 clinical study of its PSX1002 glycopyrronium bromide MDI in 37 COPD patients demonstrated statistically significant improvement in lung function compared to placebo for a range of doses. PSX1002 is a drug-only suspension formulation created using Prosonix’s proprietary particle engineering technology.
The study also showed increasing effect with increasing dose and that all doses were well tolerated, Prosonix said. The company says that the data from the study allowed it to identify two doses for a dose-ranging study set for later this year and to determine that dosing will be once-daily.
Prosonix CEO David Hipkiss commented, “These positive results represent the first clinical validation of our “Respiratory Medicine by Design” approach and as such are a significant achievement for the company. The excellent progress we are making with PSX1002 bodes well for its further development as a potential ‘best in class’ once-daily monotherapy and also for its use as part of the novel, particle-engineered, dual and triple combination products that we are developing for treating respiratory diseases.”
Read the Prosonix press release.
